Autologous adipose derived stromal vascular fraction therapeutic - Akan Biosciences
Alternative Names: Adipose-derived stromal vascular fraction therapy - Akan Biosciences; StroMel™Latest Information Update: 18 Dec 2023
At a glance
- Originator Akan Biosciences
- Class Antirheumatics; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Osteoarthritis
- Preclinical Autistic disorder; Crohn's disease; Rheumatoid arthritis; Unspecified; Wounds
Most Recent Events
- 18 Dec 2023 Preclinical trials in Crohn's disease in USA (unspecified route) (Akan bio pipeline, December 2023)
- 18 Dec 2023 Preclinical trials in Rheumatoid arthritis in USA (unspecified route) (Akan bio pipeline, December 2023)
- 18 Dec 2023 Preclinical trials in Unspecified in USA (unspecified route) (Akan bio pipeline, December 2023)